CN101869633B - 含表没食子儿茶素没食子酸酯的肠溶药物组合物 - Google Patents
含表没食子儿茶素没食子酸酯的肠溶药物组合物 Download PDFInfo
- Publication number
- CN101869633B CN101869633B CN2009101373130A CN200910137313A CN101869633B CN 101869633 B CN101869633 B CN 101869633B CN 2009101373130 A CN2009101373130 A CN 2009101373130A CN 200910137313 A CN200910137313 A CN 200910137313A CN 101869633 B CN101869633 B CN 101869633B
- Authority
- CN
- China
- Prior art keywords
- egcg
- epigallocatechin gallate
- acid
- compositions
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 171
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 104
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 52
- 239000008187 granular material Substances 0.000 claims description 18
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000005487 catechin Nutrition 0.000 claims description 16
- -1 catechin gallic acid ester Chemical class 0.000 claims description 15
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 15
- 229950001002 cianidanol Drugs 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 10
- 208000030507 AIDS Diseases 0.000 claims description 10
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 9
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 7
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 7
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 7
- 235000012734 epicatechin Nutrition 0.000 claims description 7
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 5
- 240000003152 Rhus chinensis Species 0.000 claims description 5
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 229940074391 gallic acid Drugs 0.000 claims description 5
- 235000004515 gallic acid Nutrition 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 230000006911 nucleation Effects 0.000 claims description 4
- 238000010899 nucleation Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 26
- 235000013824 polyphenols Nutrition 0.000 abstract description 25
- 241001122767 Theaceae Species 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 28
- 238000000576 coating method Methods 0.000 description 28
- 244000269722 Thea sinensis Species 0.000 description 20
- 235000013616 tea Nutrition 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000011759 adducin Human genes 0.000 description 6
- 108010076723 adducin Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000006174 pH buffer Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 3
- 229940075559 piperine Drugs 0.000 description 3
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 3
- 235000019100 piperine Nutrition 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930184207 Polyphenon Natural products 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003287 lymphocyte surface marker Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Abstract
Description
成分 | 浓度(重量%) |
甲基丙烯酸和丙烯酸乙酯(1∶1)共聚物 | 30 |
氢氧化钠溶液(1mol/L) | 10 |
水 | 60 |
滑石粉 | 9 |
成分 | 浓度(重量%) |
水 | 1.3 |
滑石粉 | 1.9 |
甲基丙烯酸和甲基丙烯酸甲酯(1∶1)共聚物 | 11 |
聚乙二醇6000 | 0.65 |
二氧化钛 | 1.25 |
异丙醇 | 84 |
成分 | 浓度(重量%) |
乙基纤维素 | 7 |
聚乙二醇6000 | 1 |
95%乙醇 | 92 |
成分 | 浓度(重量%) |
甲基丙烯酸和丙烯酸乙酯(1∶1)共聚物 | 30 |
氢氧化钠溶液(1mol/L) | 10 |
水 | 60 |
滑石粉 | 9 |
成分 | 浓度(重量%) |
水 | 1.3 |
滑石粉 | 1.9 |
甲基丙烯酸和甲基丙烯酸甲酯(1∶1)共聚物 | 11 |
聚乙二醇6000 | 0.65 |
二氧化钛 | 1.25 |
异丙醇 | 84 |
成分 | 浓度(重量%) |
乙基纤维素 | 7 |
聚乙二醇6000 | 1 |
95%乙醇 | 92 |
时间(分钟) | 普通片血药浓度(剂量:18.2mg/kg)-μg/ml | 肠溶片血药浓度(剂量:17.9mg/kg)-μg/ml | 静脉注射血药浓度(剂量:17.7mg/kg)-μg/ml |
0 | 0 | 0 | 0 |
15 | 0.350 | 0.150 | 3.745 |
30 | 0.465 | 0.205 | 3.120 |
60 | 0.533 | 0.238 | 2.348 |
90 | 0.443 | 0.507 | 2.628 |
120 | 0.357 | 0.763 | 2.368 |
180 | 0.268 | 1.138 | 2.085 |
240 | 0.217 | 0.958 | 1.842 |
360 | 0.175 | 0.722 | 1.418 |
480 | 0.158 | 0.535 | 0.800 |
720 | 0.083 | 0.310 | 0.422 |
时间(分钟) | 普通片(提取物)血药浓度(剂量:16.1mg/kg)-μg/ml | 肠溶片(提取物)血药浓度(剂量:15.9mg/kg)-μg/ml | 静脉注射(提取物)血药浓度(剂量:16.3mg/kg)-μg/ml |
0 | 0 | 0 | 0 |
15 | 0.220 | 0.170 | 3.130 |
30 | 0.389 | 0.210 | 2.940 |
60 | 0.460 | 0.201 | 2.102 |
90 | 0.414 | 0.673 | 2.015 |
120 | 0.306 | 0.796 | 1.848 |
180 | 0.202 | 0.962 | 1.625 |
240 | 0.153 | 0.994 | 1.513 |
360 | 0.120 | 0.678 | 1.246 |
480 | 0.112 | 0.452 | 0.620 |
720 | 0.062 | 0.180 | 0.257 |
血清稀释度 | 1∶1 | 1∶2 | 1∶4 | 空白血清 |
gp120与CD4+T细胞的结合率 | 32.0%±3.4% | 41.6%±4.2% | 48.7%±4.8% | 98.4%±1.2% |
血清稀释度 | 1∶1 | 1∶2 | 1∶4 | 病理模型组 | 正常对照组 |
多巴胺能神经元计数(个/孔) | 785±26 | 704±29 | 671±24 | 533±22 | 914±39 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101373130A CN101869633B (zh) | 2009-04-24 | 2009-04-24 | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101373130A CN101869633B (zh) | 2009-04-24 | 2009-04-24 | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101869633A CN101869633A (zh) | 2010-10-27 |
CN101869633B true CN101869633B (zh) | 2013-01-16 |
Family
ID=42994839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101373130A Active CN101869633B (zh) | 2009-04-24 | 2009-04-24 | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101869633B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102142539B1 (ko) * | 2012-12-11 | 2020-08-07 | 롯데정밀화학 주식회사 | 복합체 형성용 조성물, 이로부터 형성된 복합체 및 이를 포함하는 경구 섭취용 조성물 |
CN104800850A (zh) * | 2014-11-19 | 2015-07-29 | 北京康育博尔生物科技有限公司 | 一种含有egcg的口服组合物及其制备方法 |
CN105434424B (zh) * | 2015-12-08 | 2018-08-07 | 中国计量学院 | 复方肠溶保健片的制备方法 |
CN105687155B (zh) * | 2016-03-04 | 2018-01-30 | 中国计量学院 | 鱼用复方制剂的制备方法 |
CN107049992A (zh) * | 2017-05-31 | 2017-08-18 | 盛林 | 一种egcg微丸胶囊及其制备方法 |
CN107648219A (zh) * | 2017-10-17 | 2018-02-02 | 安徽农业大学 | 一种降低血清尿酸值的药品或保健品及制备方法 |
CN111249272B (zh) * | 2018-12-03 | 2023-08-15 | 深圳先进技术研究院 | 茶多酚在作为免疫检查点抑制剂及制备用于抗肿瘤的药物中的应用 |
CN109864982A (zh) * | 2019-03-22 | 2019-06-11 | 大连医诺生物股份有限公司 | 表没食子儿茶素没食子酸酯微囊粉及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444935A (zh) * | 2002-05-09 | 2003-10-01 | 华东理工大学 | 表没食子儿茶素没食子酸酯在抗肿瘤药物中应用 |
CN1548432A (zh) * | 2003-05-25 | 2004-11-24 | 浙江大学 | 儿茶素单体的稳定化方法及其药用组合物 |
CN1759844A (zh) * | 2005-09-21 | 2006-04-19 | 广州贝氏药业有限公司 | 一种克拉霉素肠溶制剂 |
CN1994294A (zh) * | 2006-12-30 | 2007-07-11 | 武汉大学 | 一种植物提取物儿茶素在制备抗病毒药物中的用途 |
CN101190910A (zh) * | 2006-11-29 | 2008-06-04 | 江和源 | 表没食子儿茶素没食子酸酯乙酰化物的制备方法 |
CN101219136A (zh) * | 2007-12-11 | 2008-07-16 | 北京协和建昊医药技术开发有限责任公司 | 一种预防和治疗艾滋病的口服胶囊剂及其制备方法 |
CN101370555A (zh) * | 2005-06-07 | 2009-02-18 | 帝斯曼知识产权资产管理有限公司 | (-)-表没食子儿茶素没食子酸酯的新型用途 |
CN101381359A (zh) * | 2008-10-15 | 2009-03-11 | 山东农业大学 | 一种从绿茶中提取高纯度表没食子儿茶素没食子酸酯的方法 |
CN101386614A (zh) * | 2008-10-24 | 2009-03-18 | 集美大学 | 树脂吸附法制备表没食子儿茶素没食子酸酯的方法 |
-
2009
- 2009-04-24 CN CN2009101373130A patent/CN101869633B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444935A (zh) * | 2002-05-09 | 2003-10-01 | 华东理工大学 | 表没食子儿茶素没食子酸酯在抗肿瘤药物中应用 |
CN1548432A (zh) * | 2003-05-25 | 2004-11-24 | 浙江大学 | 儿茶素单体的稳定化方法及其药用组合物 |
CN101370555A (zh) * | 2005-06-07 | 2009-02-18 | 帝斯曼知识产权资产管理有限公司 | (-)-表没食子儿茶素没食子酸酯的新型用途 |
CN1759844A (zh) * | 2005-09-21 | 2006-04-19 | 广州贝氏药业有限公司 | 一种克拉霉素肠溶制剂 |
CN101190910A (zh) * | 2006-11-29 | 2008-06-04 | 江和源 | 表没食子儿茶素没食子酸酯乙酰化物的制备方法 |
CN1994294A (zh) * | 2006-12-30 | 2007-07-11 | 武汉大学 | 一种植物提取物儿茶素在制备抗病毒药物中的用途 |
CN101219136A (zh) * | 2007-12-11 | 2008-07-16 | 北京协和建昊医药技术开发有限责任公司 | 一种预防和治疗艾滋病的口服胶囊剂及其制备方法 |
CN101381359A (zh) * | 2008-10-15 | 2009-03-11 | 山东农业大学 | 一种从绿茶中提取高纯度表没食子儿茶素没食子酸酯的方法 |
CN101386614A (zh) * | 2008-10-24 | 2009-03-18 | 集美大学 | 树脂吸附法制备表没食子儿茶素没食子酸酯的方法 |
Non-Patent Citations (1)
Title |
---|
赵恂等.茶多酚的指纹图谱和主要成分的含量测定方法研究.《药物分析杂志》.2007,第27卷(第3期), * |
Also Published As
Publication number | Publication date |
---|---|
CN101869633A (zh) | 2010-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101869633B (zh) | 含表没食子儿茶素没食子酸酯的肠溶药物组合物 | |
CN102397342B (zh) | 一种金荞麦提取物,含其制剂及其制备方法 | |
CN101926840B (zh) | 一种紫锥菊的超微粉散剂及其制备方法和应用 | |
WO2015192758A1 (zh) | 瓦草五环三萜皂苷类化合物抗肿瘤的药物用途 | |
CN101301455A (zh) | 一种治疗高脂血症的中药复方姜黄固体分散体 | |
CN1857418A (zh) | 一种中药干粉吸入剂和制备方法及其应用 | |
CN103860638A (zh) | 苦豆子黄酮组合物的制备方法及医药新用途 | |
CN104434826B (zh) | 一种瑞舒伐他汀钙分散片 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN102349877A (zh) | 硫酸羟氯喹胶囊、硫酸羟氯喹分散片及其应用 | |
CN101756955B (zh) | 知母宁复合物及其制备方法和应用 | |
CN1299753C (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN102153630B (zh) | 一种环八肽及其制备方法和在制药中的应用 | |
CN104383547B (zh) | 天山雪莲提取物磷脂复合物、口腔崩解片及其制备方法 | |
CN104435384B (zh) | 一种抗菌消炎缓释片剂 | |
CN101112370A (zh) | 柘树总黄酮有效部位提取物及其制备方法 | |
CN101524397B (zh) | 甘草黄酮镇咳剂及应用 | |
CN108261435A (zh) | 一种诸葛菜生物碱类提取物及其在制备保肝制品中的应用 | |
CN102198209B (zh) | 一种舒筋活血胶囊及其制备工艺 | |
CN104644601B (zh) | 一种卡培他滨片剂 | |
CN109381431A (zh) | 石杉碱甲缓释微丸及其制备方法 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
CN103142597B (zh) | 一种吐根有效成分的组合物及其制备方法和应用 | |
CN103565771A (zh) | 一种含有难溶性药物米诺膦酸的口服固体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170928 Address after: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Patentee after: JIANGSU SUZHONG PHARMACEUTICAL GROUP Co.,Ltd. Address before: Nanjing City, Jiangsu province 210016 Longpan Road No. 72 Patentee before: NANJING SUZHONG PHARMACEUTICALS RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200403 Address after: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Co-patentee after: NANJING SUZHONG PHARMACEUTICALS RESEARCH Co.,Ltd. Patentee after: Jiangsu Suzhong Pharmaceutical Group Co.,Ltd. Address before: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Patentee before: Jiangsu Suzhong Pharmaceutical Group Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Patentee after: JIANGSU SUZHONG PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Jiangsu Suzhong Pharmaceutical Research Institute Co.,Ltd. Address before: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Patentee before: Jiangsu Suzhong Pharmaceutical Group Co.,Ltd. Patentee before: NANJING SUZHONG PHARMACEUTICALS RESEARCH Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.1 Suzhong Road, Jiangyan District, Taizhou City, Jiangsu Province 225500 Patentee after: Suzhong Pharmaceutical Group Co.,Ltd. Patentee after: Jiangsu Suzhong Pharmaceutical Research Institute Co.,Ltd. Address before: No.1 Suzhong Road, Jiangyan District, Taizhou City, Jiangsu Province 225500 Patentee before: JIANGSU SUZHONG PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Jiangsu Suzhong Pharmaceutical Research Institute Co.,Ltd. |